Cara Therapeutics (CARA) Reports In-Line Q3 EPS

Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $4.87 million versus the consensus estimate of $9.95 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• IBM plunges 19% as memory capex squeeze derails Q2 earnings
• Soluna added to Russell indexes, signs LOI for 350 MW AI project
• Cal-Maine Foods (CALM) PT Lowered to $85 at Stephens